Document is current
Any future updates will be listed below
-
Authors
Lu, Xinyan
Andersen, Erica F.
Banerjee, Rahul https://orcid.org/0000-0003-3781-5441
Eno, Celeste C. https://orcid.org/0000-0002-3857-9519
Gonzales, Patrick R.
Kumar, Shaji https://orcid.org/0000-0001-5392-9284
Lager, Angela M.
Miron, Patricia M.
Pugh, Trevor
Quintero-Rivera, Fabiola
Thurston, Virginia C. https://orcid.org/0009-0006-2569-3511
Wolff, Daynna J.
Zhao, Jian
Fonseca, Rafael https://orcid.org/0000-0002-5938-3769
Baughn, Linda B. https://orcid.org/0000-0001-5229-4897
- License Information
-
More Information
Article History
Received: 13 January 2025
Revised: 9 April 2025
Accepted: 14 April 2025
First Online: 18 June 2025
Competing interests
: EA reports consultancy AbbVie. RB reports consultancy Adaptive Biotech, BMS, Caribou Biosciences, Genentech, Janssen, Karyopharm, Legend Biotech, Pfizer, Sanofi, SparkCures; Research: Novartis, Pack Health. RF reports consultancy for AbbVie, Adaptive Biotechnologies, AMGEN, AZeneca, Bayer, Binding Site, BMS (Celgene), Millenium Takeda, Jansen, Juno, Kite, Merck, Pfizer, Pharmacyclics, Regeneron, Sanofi; scientific advisory boards for Adaptive Biotechnologies, Caris Life Sciences, Oncotracker; board of directors for Antegene, AZBio; and patents for FISH in myeloma. SK reports consultancy from BMS/Celgene, Takeda and Janssen and research funding from BMS (Celgene), Takeda, Novartis, AbbVie, Janssen and Amgen. LBB reports consultancy Genentech. The remaining authors have no interests to disclose.
